Three Different Studies Target Androgen Receptors in Breast Cancer

Three Different Studies Target Androgen Receptors in Breast Cancer
shutterstock_2663970During the 2014 San Antonio Breast Cancer Symposium, three studies presented by researchers from the University of Colorado Cancer Center showed the outcomes of androgen receptor blockade in breast cancer. The first study demonstrated that this blockade lowers the growth of estrogen-positive (ER+) breast cancers, while the second study showed that triple-negative breast cancers (TNBCs) that should not be sensitive to hormonal stimuli and have a low prognosis, rely on androgen receptor activation. In the third study, researchers found that blocking androgen receptors together with HER2 or mTOR had an enhanced effect, resulting in increased cancer cell death. "We're on the cusp of a major revolution in the way we treat breast cancer. We've known for years that prostate cancer is driven by androgens and now it's increasingly clear that androgens and androgen receptors can influence many breast cancers as well. AR is actually even more prevalent in breast cancer than estrogen or progesterone receptors. Targeting androgen receptors in breast cancer gives us an new way to attack the disease," Jennifer Richer, PhD, investigator at the CU Cancer Center and head of the Richer Laboratory that produced the results, said in a recent
Subscribe or to access all post and page content.